Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the sellers in connection with the divestment of Johan i Hallen & Bergfalk
Mandate

Vinge advises the sellers in connection with the divestment of Johan i Hallen & Bergfalk

May 04, 2023 Banking and Finance M&A

Vinge advises the sellers, represented by Litorina V Fund, in connection with the divestment of JOHBECO AB (including its Swedish and Finnish subsidiaries Johan i Hallen & Bergfalk) to METRO FSD Holding GmbH, an indirect subsidiary of international wholesaler METRO AG.

Johan i Hallen & Bergfalk operates on the Swedish and Finnish markets and is a leading Swedish specialist provider of high quality fresh proteins such as meat, fish and seafood to restaurants, hotels and cafés.

Vinge’s team consisted of Jonas Johansson, Carl Sander, Desirée Hagenfeldt and Robin Sultani (M&A) and Karl-Gustaw Tobola (Bank & Financing) as well as Julia Hagelberg, Emy Rydén and Anna Ekdahl Roos (project assistants).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026